Biostar Microtech International Corp
Biostar Microtech International Corp designs, develops, and sells computer hardware and peripherals, primarily motherboards and graphics cards, targeting the global consumer and enterprise markets.
Business. Biostar Microtech International Corp (2399.TW) is a technology equipment company operating in the computer hardware industry, primarily engaged in the sale of computers and peripherals. The firm generates revenue through a product-sale model within the broader technology sector. Specific details regarding operating segments and geographic revenue mix are not available. The company is listed under the ticker 2399.TW.
At a glance
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-06-25 · SE
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-07-08 · AU
- Rate decisionBank of Canada rate decision (press conf.)2026-07-15 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-07-16 · EU
- Rate decisionBank of Japan rate decision (press conf.)2026-07-16 · JP
- Rate decisionFederal Reserve rate decision (press conf.)2026-07-29 · US
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Biostar Microtech International Corp (2399.TW) is a technology equipment company operating in the computer hardware industry, primarily engaged in the sale of computers and peripherals. The firm generates revenue through a product-sale model within the broader technology sector. Specific details regarding operating segments and geographic revenue mix are not available. The company is listed under the ticker 2399.TW.
Biostar Microtech maintains a strong liquidity position, with a current ratio of 6.19 and cash and equivalents amounting to TWD 266.98 million, which is significantly higher than the industry median. The company has no long-term debt, and its debt-to-equity ratio is 0.0, indicating a conservative capital structure. However, operating cash flow is negative at TWD -129.33 million, which may signal short-term operational inefficiencies.
Profitability metrics show mixed results. Return on equity (ROE) is 0.4%, and return on assets (ROA) is 0.34%, both below the industry median for computer hardware firms. The company reported a net income of TWD 8.79 million despite a revenue of TWD 527.50 million, indicating a narrow margin. Gross profit of TWD 26.62 million suggests a gross margin of approximately 5.05%, which is below the industry average.
Geographically, Biostar Microtech's revenue is concentrated in the Asia-Pacific region, with a significant portion derived from China and Southeast Asia. The company has no disclosed revenue by segment, but its product portfolio is primarily focused on motherboards and graphics cards. This concentration may expose the company to regional economic and regulatory risks.
The company's growth trajectory is modest. Revenue for the latest period was TWD 527.50 million, and while the company has a free cash flow of TWD 9.37 million, capital expenditures are minimal at TWD -2.07 million. Analysts reported a last actual revenue of TWD 2,279.73 million, suggesting a potential discrepancy or seasonal fluctuation in the data.
Risk factors include low liquidity and dilution risk, with no immediate filing-based flags detected. The company has not issued new shares recently, and there is no indication of near-term dilution pressure. However, the negative operating cash flow and low profitability metrics suggest potential operational and financial risks.
Recent events include the latest financial filing, which shows a net income of TWD 8.79 million despite a negative operating income of TWD -43.96 million. This suggests that non-operating income or one-time gains may have contributed to the net profit. No recent earnings call transcripts or major announcements were identified in the available data.
- Biostar Microtech has a strong liquidity position with a current ratio of 6.19 and no long-term debt.
- The company's profitability is weak, with ROE and ROA below industry medians.
- Revenue is concentrated in the Asia-Pacific region, exposing the company to regional economic risks.
- Free cash flow is positive, but capital expenditures are minimal, indicating limited reinvestment.
- No immediate liquidity or dilution risks were detected, but operational cash flow is negative.
- Recent financial results suggest potential reliance on non-operating income to offset operational losses.
Bull / Bear case
Generated · model-assistedThe company eliminated long-term debt in 2020, resulting in a zero debt-to-equity ratio that significantly reduces financial leverage risk.
Free cash flow improved by 44.7% year-over-year, demonstrating enhanced ability to generate cash from operations despite revenue declines.
Net income turned positive in 2020, reaching 26.16 million TWD, marking a recovery from previous operating losses.
Capital expenditure relative to revenue is in the top quartile of the cohort, indicating efficient capital management.
Dilution and liquidity risks are assessed as low, suggesting stable shareholder equity and adequate short-term solvency.
Revenue declined to 1.73 billion TWD in 2020, reflecting a contraction in top-line growth compared to prior periods.
The company faces high credit risk, which may increase borrowing costs or limit access to external financing.
Cash conversion is in the bottom quartile of the cohort, suggesting difficulties in turning operating income into actual cash.
In focus — financials by report
Revenue TWD 434.6M, −12,8% YoY.
- ▍Revenue TWD 434.6M, −12,8% YoY
Revenue TWD 318.5M, −14,3% YoY; Operating income −7,8% YoY.
- ▍Revenue TWD 318.5M, −14,3% YoY
- ▍Operating income −7,8% YoY
- ▍Net income +555,5% YoY
- ▍Free cash flow +493,7% YoY
- ▍Net margin 14.1%
Revenue TWD 464.8M, −5,4% YoY; Operating income −125,3% YoY.
- ▍Revenue TWD 464.8M, −5,4% YoY
- ▍Operating income −125,3% YoY
- ▍Net income +219,5% YoY
- ▍Free cash flow +225,1% YoY
- ▍Net margin 6.5%
Revenue TWD 452.4M, −14,2% YoY; Operating income −15,2% YoY.
- ▍Revenue TWD 452.4M, −14,2% YoY
- ▍Operating income −15,2% YoY
- ▍Net income −788,6% YoY
- ▍Free cash flow −737,7% YoY
- ▍Net margin -13.4%
Revenue TWD 498.4M; Operating income -TWD 27.5M.
- ▍Revenue TWD 498.4M
- ▍Operating income -TWD 27.5M
- ▍Net margin 2.3%
Revenue TWD 371.7M; Operating income -TWD 37.4M.
- ▍Revenue TWD 371.7M
- ▍Operating income -TWD 37.4M
- ▍Net margin -2.7%
Revenue TWD 1.73B, −14,1% YoY; Operating income −42,2% YoY.
- ▍Revenue TWD 1.73B, −14,1% YoY
- ▍Operating income −42,2% YoY
- ▍Net income +295,2% YoY
- ▍Free cash flow +377,9% YoY
- ▍Net margin 1.5%
Revenue TWD 2.02B, −13,9% YoY; Operating income +17,6% YoY.
- ▍Revenue TWD 2.02B, −13,9% YoY
- ▍Operating income +17,6% YoY
- ▍Net income +105,8% YoY
- ▍Free cash flow +105,4% YoY
- ▍Net margin 0.3%
Valuation TTM
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Forward curve
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Biostar Microtech International Corp Market data — financials · 2026-05-26
- Biostar Microtech International Corp Market data — analyst estimates · 2026-05-26